Abstract
The high-risk clones of Acinetobacter baumannii, called international clones (ICs), span several ICs, IC1 to IC7 being the most reported. Among them, IC2 represents the main lineage causing outbreaks worldwide. IC2 presents a great diversity of sub-lineages with different sequence types (ST). Despite successful global spread, the occurrence of IC2 is rarely reported in Latin America, including Brazil. Here, through genomic analysis, we investigated 16 IC2/ST2 strains obtained from a clinical setting in Brazil (2022). These strains represented carbapenem-resistant A. baumannii (CRAB) with an extensively drug-resistant (XDR) profile, with most showing some resistance to tigecycline. Overall, these strains showed susceptibility only to polymyxins, thus leading to restricted therapeutic choices. Based on in silico analysis, the relationship between Brazilian CRAB genomes and IC2/ST2 genomes circulating in the world, particularly in South America, was established. The Brazilian IC2 strains belonged to three discrete and distinct sub-lineages, being more associated with IC2/ST2 genomes from countries in Europe, North America and Asia, suggesting their epidemiological link. These Brazilian strains were characterized by the co-presence of blaOXA-23 and blaOXA-66, in addition to the genes APH(6), APH(3”), ANT(3”), AAC(6’), armA, and the efflux pumps adeABC and adeIJK, associated with the XDR/CRAB phenotype. Furthermore, the three sub-lineages presented three distinct capsules, KL7, KL9 and KL56, the latter not yet associated with IC2 genomes. A large set of virulence genes was also identified in the genomes: adeFGH/efflux pump, the siderophores barAB, basABCDFGHIJ and bauBCDEF, lpxABCDLM/capsule, tssABCDEFGIKLM/T6SS, pgaABCD/biofilm.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Este estudo foi financiado pela FAPERJ - Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de Janeiro, Processo SEI-260003/019688/2022
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript
